Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Nivolumab
Treatment for Brain and central nervous system cancer
Typical Dosage: 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Effectiveness
20%
Safety Score
40%
Clinical Trials
41
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
40
DangerousModerateSafe
Treatment Details
Dosage Range
240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Time to Effect
2-4 months
Treatment Duration
6-12 months
Evidence Quality
HIGHNumber Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$10,000
Side Effect Mgmt:$8,000
Total Annual:$168,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORQALYs Gained
0
Outcome-Based Costs
Cost per Responder
$2,100,000
Comparison vs Bevacizumab
Cost Difference
+$58,000/year
More expensive
QALY Difference
-0.01 QALYs
Worse outcomes
Dominance
No dominance
Nivolumab Outcomes
for Brain and central nervous system cancer
Efficacy Outcomes
Overall Effectiveness
+20%
Response Rate
+8%
Remission Rate
+1%
Common Side Effects
Fatigue
+25%
Rash
+15%
Diarrhea
+15%
Immune-related adverse events
+10%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
7 active trials recruiting for Nivolumab in Brain and central nervous system cancer
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
NCT07017816RECRUITINGEARLY_PHASE1
18 participants
INTERVENTIONAL
Washington D.C., United States
Started: Dec 16, 2025
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
NCT02374242ACTIVE NOT RECRUITINGPHASE2
76 participants
INTERVENTIONAL
Wollstonecraft, Australia +3 more
Started: Nov 4, 2014
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
NCT04042753ACTIVE NOT RECRUITINGPHASE2
9 participants
INTERVENTIONAL
Los Angeles, United States +7 more
Started: Jul 31, 2019
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
NCT06712927RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Palo Alto, United States
Started: Aug 6, 2025
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
NCT07210632RECRUITINGEARLY_PHASE1
38 participants
INTERVENTIONAL
Nashville, United States
Started: Mar 27, 2026
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
NCT06208657RECRUITINGPHASE1, PHASE2
90 participants
INTERVENTIONAL
Newcastle, Australia +13 more
Started: Jul 10, 2024
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
NCT05048212RECRUITINGPHASE2
20 participants
INTERVENTIONAL
Houston, United States
Started: Sep 20, 2022
Completed Clinical Trials
9 completed trials for Nivolumab in Brain and central nervous system cancer
Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma
NCT04022980COMPLETEDPHASE1
14 participants
INTERVENTIONAL
Brookline, United States +3 more
Started: Mar 31, 2020
An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
NCT02617589COMPLETEDPHASE3
560 participants
INTERVENTIONAL
Birmingham, United States +124 more
Started: Mar 1, 2016
Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade Gliomas
NCT03925246COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Bordeaux, France +6 more
Started: Jul 30, 2019
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
NCT03807765COMPLETEDPHASE1
14 participants
INTERVENTIONAL
Tampa, United States
Started: Jan 30, 2019
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
NCT02658981COMPLETEDPHASE1
63 participants
INTERVENTIONAL
Birmingham, United States +10 more
Started: Aug 24, 2016
Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
NCT03173950COMPLETEDPHASE2
133 participants
INTERVENTIONAL
Chicago, United States +2 more
Started: Jul 13, 2017
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
NCT02716948COMPLETEDPHASE1
17 participants
INTERVENTIONAL
Baltimore, United States
Started: Jun 23, 2016
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
NCT02978404COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Montreal, Canada +3 more
Started: Jun 2, 2017
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
NCT05704933COMPLETEDEARLY_PHASE1
1 participants
INTERVENTIONAL
Tampa, United States +1 more
Started: Jun 6, 2023
Showing 20 of 43 total trials